<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904043</url>
  </required_header>
  <id_info>
    <org_study_id>201904029</org_study_id>
    <nct_id>NCT03904043</nct_id>
  </id_info>
  <brief_title>Non-Operative Management and Early Response Assessment in Rectal Cancer</brief_title>
  <acronym>NOM-ERA</acronym>
  <official_title>Non-Operative Management and Early Response Assessment in Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' data from a phase I study of short course radiation therapy followed by&#xD;
      chemotherapy showed 74% complete clinical response (cCR). Given the promising response rate,&#xD;
      the investigators are evaluating short course radiation therapy (SCRT) followed by&#xD;
      chemotherapy in a multi-institution phase II trial to validate the cCR rate of this treatment&#xD;
      paradigm. SCRT has not been prospectively evaluated in non-operative management for patients&#xD;
      with non-metastatic rectal adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical complete response rate</measure>
    <time_frame>Completion of treatment (estimated to be 22 weeks)</time_frame>
    <description>-Criteria for clinical complete response:&#xD;
No residual gross tumor at procto/sigmoidoscopy;, or only erythematous scar or ulcer&#xD;
No palpable tumor on DRE&#xD;
No radiographic evidence of tumor on MRI&#xD;
No suspicious mesorectal lymph nodes on MRI&#xD;
Negative biopsy from scar, ulcer, or former tumor site (if necessary according to surgeon's judgment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Criteria for progressive disease&#xD;
*Increase in the size of primary tumor by RECIST criteria&#xD;
New metastatic disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 or higher toxicity during treatment</measure>
    <time_frame>Completion of treatment (estimated to be 22 weeks)</time_frame>
    <description>-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post chemoradiotherapy grade 3 or higher toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of anorectal function as measured by the FACT-C questionnaire</measure>
    <time_frame>1 year (between 10-14 months post treatment start date)</time_frame>
    <description>Questionnaire with 5 sections (physical well-being, social/family well being, emotional well-being, functional well-being, and additional concerns)&#xD;
Answers to the questions range from 0=not at all to 4=very much. The higher the total score the lower quality of life the person has</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ preservation rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ preservation rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Adenocarcinoma of the Lower Rectum</condition>
  <arm_group>
    <arm_group_label>Radiation + FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pelvic radiotherapy 5GY x 5 fractions once daily&#xD;
Radiation to extra-mesorectal node 7 Gy x 5 fractions once daily&#xD;
FOLFOX should begin 2-4 weeks after completion of radiotherapy and will consist of FOLFOX x 8 cycles (16 weeks).&#xD;
Oxaliplatin day 1 every 14 days&#xD;
Leucovorin day 1 every 14 days&#xD;
5-FU bolus day 1 every 14 days&#xD;
5-FU infusion day 1 every 14 days over 46 hours&#xD;
Alternatively CAPOX (capecitabine and oxaliplatin) may be given for 5 cycles over 15 weeks.&#xD;
An optional simultaneous integrated boost of 30 Gy in 5 fractions to the primary tumor is permitted</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>-Monday-Friday treatment is strongly recommended</description>
    <arm_group_label>Radiation + FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
    <description>-CAPOX can be given as alternative</description>
    <arm_group_label>Radiation + FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire</intervention_name>
    <description>-Baseline, completion of chemotherapy (3-8 weeks after the end of chemotherapy), and 10 to 14 months after radiotherapy</description>
    <arm_group_label>Radiation + FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal biopsy samples</intervention_name>
    <description>-Multiple biopsy samples of the rectal tumor will be taken from the patient tumor prior to treatment initiation for genomic extraction. For patients at affiliate sites who do not have enough tissue from the diagnostic biopsy, a repeat pre-treatment biopsy is optional.</description>
    <arm_group_label>Radiation + FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood for ctDNA</intervention_name>
    <description>-Prior to the start of treatment, Post radiation therapy labs (with standard of care (SOC) CBC/CMP prior to start of cycle 1 of chemotherapy), Day 1 of cycle 2 of chemotherapy (with SOC CBC/CMP), Completion of chemotherapy (3-8 weeks after the end of chemotherapy), months 3, 6, 9, 12, 16, 20, 24 until salvage surgery or 2 years from completion of chemotherapy (whichever is first)</description>
    <arm_group_label>Radiation + FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of biopsy proven stage I-IIIB (cT1-3, N0-2a, M0) adenocarcinoma of the&#xD;
             rectum; staging must also be based on multidisciplinary evaluation including MRI&#xD;
&#xD;
          -  Tumor â‰¤ 12 cm from anal verge as determined by MRI or endoscopy&#xD;
&#xD;
          -  Clinically detectable (MR, endoscopy, or DRE) tumor present&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Adequate bone marrow function defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 1,500 cells/mm3&#xD;
&#xD;
               -  Hemoglobin&gt; 8 g/dl&#xD;
&#xD;
               -  Platelets &gt;100,000 cells/mm3&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control, abstinence) prior to study entry and for&#xD;
             the duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she must inform her treating physician&#xD;
             immediately.&#xD;
&#xD;
          -  Able to understand and willing to sign an Institutional Review Board (IRB)-approved&#xD;
             written informed consent document.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Prior radiation therapy, chemotherapy or extirpative surgery for rectal cancer.&#xD;
&#xD;
          -  Prior oxaliplatin or capecitabine use for any malignancy&#xD;
&#xD;
          -  No prior radiation therapy to the pelvis.&#xD;
&#xD;
          -  A history of other malignancy with the exception of malignancies for which all&#xD;
             treatment was completed at least 2 years before registration and the patient has no&#xD;
             evidence of disease.&#xD;
&#xD;
          -  Currently receiving any investigational agents.&#xD;
&#xD;
          -  A history of allergic reaction attributed to compounds of similar chemical or biologic&#xD;
             composition to capecitabine, 5FU, oxaliplatin, or leucovorin.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac&#xD;
             arrhythmia.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative&#xD;
             serum pregnancy test within 14 days of study entry.&#xD;
&#xD;
          -  Patients with HIV are eligible unless their CD4+ T-cell counts are &lt; 350 cells/mcL or&#xD;
             they have a history of AIDS-defining opportunistic infection within the 12 months&#xD;
             prior to registration. Concurrent treatment with effective antiretroviral therapy&#xD;
             (ART) according to Department of Health and Human Services (DHHS) treatment guidelines&#xD;
             is recommended. HIV testing for patients without a history of HIV is not a protocol&#xD;
             requirement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Kim, M.D.</last_name>
    <phone>314-362-8502</phone>
    <email>kim.hyun@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Olsen, M.D.</last_name>
      <phone>719-365-6800</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Olsen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Hallemeier, M.D.</last_name>
      <email>hallemeier.christopher@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Hallemeier, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Kim, M.D.</last_name>
      <phone>314-362-8502</phone>
      <email>kim.hyun@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Hyun Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manik Amin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean Glasgow, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kian-Huat Lim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haeseong Park, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Mutch, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Silviera, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Suresh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin R Tan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikolaos Trikalinos, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Wise, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Huang, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David DeNardo, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Radhika Smith, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauren Henke, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shahed Badiyan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela Samson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl DeSelm, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia Aranha, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Anker, M.D.</last_name>
      <phone>802-847-3506</phone>
      <email>chris.anker@uvmhealth.org</email>
    </contact>
    <investigator>
      <last_name>Chris Anker, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Ades, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maura Berry, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Greenblatt, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nataniel Lester-Coll, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Cataldo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesse Moore, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krista Evans, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data will be shared with investigators who submit a sound proposal. Participants who opted out of data sharing in the informed consent will not be included.</ipd_description>
    <ipd_time_frame>Up to 5 years after completion of the study</ipd_time_frame>
    <ipd_access_criteria>Proposals should be directed to kim.hyun@wustl.edu. To gain access, data requestors will need to sign a data access agreement and provide proof of appropriate regulatory approvals as necessary.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

